Seroatlas · Human Serome Atlas

IFI30

Gamma-interferon-inducible lysosomal thiol reductase

Also known as: GILT, GILT_HUMAN, IFI-30, IP-30, IP30, MGC32056

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: P13284
Gene: IFI30
Ensembl: ENSG00000216490
Chromosome: 19
Canonical length: 250 aa
Protein class: Predicted intracellular proteins, Predicted membrane proteins
Subcellular location: Vesicles,Cytosol
Secretome location: Intracellular and membrane

OverviewNCBI Gene

The protein encoded by this gene is a lysosomal thiol reductase that at low pH can reduce protein disulfide bonds. The enzyme is expressed constitutively in antigen-presenting cells and induced by gamma-interferon in other cell types. This enzyme has an important role in MHC class II-restricted antigen processing. [provided by RefSeq, Jul 2008]

Canonical amino-acid sequenceUniProt

250 residues, UniProt reviewed canonical sequence.

>P13284|IFI30
     1  MTLSPLLLFL PPLLLLLDVP TAAVQASPLQ ALDFFGNGPP VNYKTGNLYL RGPLKKSNAP
    61  LVNVTLYYEA LCGGCRAFLI RELFPTWLLV MEILNVTLVP YGNAQEQNVS GRWEFKCQHG
   121  EEECKFNKVE ACVLDELDME LAFLTIVCME EFEDMERSLP LCLQLYAPGL SPDTIMECAM
   181  GDRGMQLMHA NAQRTDALQP PHEYVPWVTV NGKPLEDQTQ LLTLVCQLYQ GKKPDVCPSS
   241  TSSLRSVCFK

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against IFI30 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Secreted
Secreted: Yes
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.38
Highest tissue expression: 668 nTPM

Expression across tissuesHPA

Tissue

appendix: 668 nTPM
lung: 540 nTPM
spleen: 443 nTPM
lymph node: 347 nTPM
choroid plexus: 286 nTPM
bone marrow: 268 nTPM

Single-cell type

microglia: 27 nCPM
monocytes: 27 nCPM
ependymal cells: 2.5 nCPM
choroid plexus epithelial cells: 2.4 nCPM
b-cells: 2.1 nCPM
kupffer cells: 2 nCPM

Immune cell

intermediate monocyte: 14,264 nTPM
total PBMC: 11,087 nTPM
non-classical monocyte: 9,917 nTPM
classical monocyte: 9,529 nTPM
myeloid DC: 5,707 nTPM
eosinophil: 3,902 nTPM

Brain region

thalamus: 116 nTPM
white matter: 75 nTPM
choroid plexus: 72 nTPM
pons: 54 nTPM
cerebral cortex: 41 nTPM
medulla oblongata: 38 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about IFI30.

Disease | ImmuneIEDB

Conditions an epitope on IFI30 was assayed in.

type 1 diabetes mellitus T cell

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.51
gnomAD pLI: 0
gnomAD missense Z: 0.63
DepMap mean gene effect: -0.03
DepMap dependency class: none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

Gamma interferon inducible lysosomal thiol reductase GILT
Gamma interferon inducible lysosomal thiol reductase (GILT)

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of IFI30 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

DAPK1

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads IFI30 as an antibody target. Whether an autoantibody or antibody against IFI30 could matter depends on whether native IFI30 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

IFI30 is annotated as secreted, so native IFI30 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.

Annotation status

The present source text does not explicitly label IFI30 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...